Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis

Since the advent of biological disease modifying anti-rheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA), most RA patients receiving such drugs have achieved remission at the expense of cost and infection risk. After bDMARDs are withdrawn, a substantial proportion of patients wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakashita, Eiji, Nagatani, Katsuya, Endo, Hitoshi, Minota, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529916/
https://www.ncbi.nlm.nih.gov/pubmed/36192530
http://dx.doi.org/10.1038/s41598-022-21160-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529916/
https://www.ncbi.nlm.nih.gov/pubmed/36192530
http://dx.doi.org/10.1038/s41598-022-21160-0

Ejemplares similares